AKF summit seeks to improve diagnosis of underlying causes of kidney diseases
The American Kidney Fund recently announced it will convene a summit of scientists, patients, and academic and industry researchers in spring 2020 to advance the diagnosis and treatment of the underlying causes of kidney diseases, according to a press release from the AKF.
Initial leadership funding for the initiative is provided by Sanofi Genzyme, with other partners expected to join the effort in 2020.
“Kidney disease has become more of a national priority than ever before with the federal government’s Advancing American Kidney Health initiative, which is helping to spur innovation in research and treatment for this disease that affects so many Americans,” LaVarne A. Burton, president and CEO of the AKF, said in the release. “This new AKF initiative will help to assess and address the gap in patient care that occurs when the underlying cause of kidney disease is not identified.”
A committee of scientists and patients with experience in this area will help plan the spring summit and bring together a broad coalition working group. Summit participants will review research, discuss available or potential data sets, identify barriers to progress and develop a strategic plan to address the information gap.
According to Burton, “the patient voice will be central to this project, which is an opportunity to foster greater collaboration across disciplines in nephrology research with the ultimate goal of improving patient outcomes. We are grateful to Sanofi Genzyme for signing on as a lead sponsor for this initiative and look forward to welcoming a coalition of additional partners to support this important work.”